Hikma Pharmaceuticals has requested the full Federal Circuit’s intervention following a panel decision that necessitates the company to face infringement litigation. This legal challenge concerns Hikma’s generic version of Amarin Pharma Inc.’s highly successful cardiovascular medication, Vascepa.
Hikma’s appeal to the full Federal Circuit emphasizes the significance of this case to the pharmaceutical industry, particularly concerning the application of “skinny labels” by generic drug manufacturers. These labels allow for partial market entry, mitigating infringement risks by excluding patent-protected uses. The outcome of this litigation could have broad implications for generic drug policies and patent litigation strategies.
For more details, read the full coverage on Law360.